Advertisement

Human Anti-antibody Response

  • Natalie L. Griffin
  • Hassan Shahbakhti
  • Surinder K. SharmaEmail author
Protocol
  • 1.9k Downloads
Part of the Springer Protocols Handbooks book series (SPH)

Abstract

Antibodies are emerging as a new drug class with many of these approved and marketed. Antibodies may be non-human, chimeric, humanized or fully human. All these have the potential to elicit an immune response in the host which may impact on safety and efficacy. Therefore, assessment of immunogenicity of the therapeutic protein is an essential part of its clinical development. This involves testing strategies which provide relevant information on antibody responses. This chapter describes a simple ELISA method to detect human anti-antibody response.

Keywords

Therapeutic Protein Phosphate Citrate Buffer Assay Validation Negative Control Sample Direct ELISA 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Aarden L, Ruuls SR, Wolbink G (2008) Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 20:431–435PubMedCrossRefGoogle Scholar
  2. Avramis VI, Avramis EV, Hunter W, Long MC (2009) Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL). Anticancer Res 29:299–302PubMedGoogle Scholar
  3. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343–357PubMedCrossRefGoogle Scholar
  4. De Groot AS, Scott DW (2007) Immunogenicity of protein therapeutics. Trends Immunol 28:482–490PubMedCrossRefGoogle Scholar
  5. Findlay JW, Smith WC, Lee JW, Nordblom GD, Das I, DeSilva BS, Khan MN, Bowsher RR (2000) Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal 21:1249–1273PubMedCrossRefGoogle Scholar
  6. Geng D, Shankar G, Schantz A, Rajadhyaksha M, Davis H, Wagner C (2005) Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J Pharm Biomed Anal 39:364–375PubMedCrossRefGoogle Scholar
  7. Hale G (2006) Therapeutic antibodies – delivering the promise? Adv Drug Deliv Rev 58:633–639PubMedCrossRefGoogle Scholar
  8. Horninger D, Eirikis E, Pendley C, Giles-Komar J, Davis HM, Miller BE (2005) A one-step, competitive electrochemiluminescence-based immunoassay method for the quantification of a fully human anti-TNFalpha antibody in human serum. J Pharm Biomed Anal 38:703–708PubMedCrossRefGoogle Scholar
  9. Koren E, Smith HW, Shores E, Shankar G, Finco-Kent D, Rup B, Barrett YC, Devanarayan V, Gorovits B, Gupta S, Parish T, Quarmby V, Moxness M, Swanson SJ, Taniguchi G, Zuckerman LA, Stebbins CC, Mire-Sluis A (2008) Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 333:1–9PubMedCrossRefGoogle Scholar
  10. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D, Zuckerman LA (2004) Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 289:1–16PubMedCrossRefGoogle Scholar
  11. Presta LG (2006) Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 58:640–656PubMedCrossRefGoogle Scholar
  12. Schellekens H (2002) Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24:1720–1740PubMedCrossRefGoogle Scholar
  13. Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5:147–159PubMedCrossRefGoogle Scholar
  14. Shankar G, Pendley C, Stein KE (2007) A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 25:555–561PubMedCrossRefGoogle Scholar
  15. Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, Fiscella M, Gorovits B, Kirschner S, Moxness M, Parish T, Quarmby V, Smith H, Smith W, Zuckerman LA, Koren E (2008) Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 48:1267–1281PubMedCrossRefGoogle Scholar
  16. Sharma SK, Bagshawe KD, Melton RG, Sherwood RF (1992) Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys 21:109–120PubMedGoogle Scholar
  17. Thorpe R, Swanson SJ (2005) Current methods for detecting antibodies against erythropoietin and other recombinant proteins. Clin Diagn Lab Immunol 12:28–39PubMedGoogle Scholar
  18. Wadhwa M, Thorpe R (2006) Strategies and assays for the assessment of unwanted immunogenicity. J Immunotoxicol 3:115–121PubMedCrossRefGoogle Scholar
  19. Wadhwa M, Bird C, Dilger P, Gaines-Das R, Thorpe R (2003) Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J Immunol Methods 278:1–17PubMedCrossRefGoogle Scholar
  20. White JT, Martell LA, Van TA, Boyer R, Warness L, Taniguchi GT, Foehr E (2008) Development, validation, and clinical implementation of an assay to measure total antibody response to naglazyme (galsulfase). AAPS J 10:363–372PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Natalie L. Griffin
    • 1
  • Hassan Shahbakhti
    • 1
  • Surinder K. Sharma
    • 1
    Email author
  1. 1.UCL Cancer InstituteLondonUK

Personalised recommendations